Acadia Pharmaceuticals | ACAD - Umsatzerlöse

Aktienkurs
22.06
Täglich Wechseln
0.60 2.77%
Monatlich
3.11%
Jährlich
47.13%
Q2 Prognose
21.15




Der Umsatz Veränderung Datum
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 202.12M 5.48M 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Eisai JPY 219.94B 22.58B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Incyte USD 1.51B 140M 2025-12
J&J USD 24.1B 500M 2026-03
Moderna USD 678M 342M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pfizer USD 17.58B 880M 2025-12
Prothena USD 21K 2.4M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12